Charts

Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript March 28, 2024 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.94, expectations were $-1.02. ITRM isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, everyone, and welcome to the […]

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

Q4 2023 Iterum Therapeutics PLC Earnings Call

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. The post ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

--Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today r

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

Iterum Therapeutics (NASDAQ:ITRM) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors ...

DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Thursday, March 28, 2024. M

Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 13.9% to $2.71 during Wednesday's after-market session. The market ...

DUBLIN, Ireland and CHICAGO, March 15, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, announced today that the company will participate in a virtual H.C. Wainwright @Home Fireside Chat on March 21, 2024. Corey Fishman, Iterum’s Chief Executive Officer, Sailaja Puttagunta, M.D., Iterum’s Chief

Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.

Resubmission of NDA is On Track for First Half of Q2 24 Extended Cash Runway into 2025 DUBLIN, Ireland and CHICAGO, March 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today provided a general business update. Iterum announced that it now expects to resubmit its new drug application (NDA)

Gainers KalVista Pharma (NASDAQ:KALV) stock moved upwards by 31.5% to $21.1 during Tuesday's pre-market session. The market value of ...

On January 30, 2024, Steven Cohen (Trades, Portfolio)'s Point72 Asset Management made a significant move in the pharmaceutical sector by purchasing 850,001 shares of Iterum Therapeutics PLC (NASDAQ:ITRM), an Ireland-based clinical-stage pharmaceutical company. The transaction was executed at a trade price of $1.58 per share, marking a new holding for the firm in its diverse investment portfolio. This strategic buy reflects Cohen's confidence in Iterum Therapeutics, despite the company's current market capitalization of $21.095 million and a stock price closely trailing the trade price at $1.57.

Gainers SINTX Techs (NASDAQ:SINT) shares increased by 75.0% to $0.41 during Tuesday's after-market session. The market value of their ...

Iterum Therapeutics PLC (NASDAQ:ITRM) shares are trending Tuesday after the company announced its Phase 3 Reassure trial met the primary ...

Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin®

The Dow Jones index closed higher by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence ...

DUBLIN, Ireland and CHICAGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained com

Gainers Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 62.0% to $1.62 during Tuesday's regular session. The market value of ...

Gainers LumiraDx (NASDAQ:LMDX) shares rose 42.8% to $0.14 during Thursday's regular session. LumiraDx's stock is trading at a volume of ...

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Hello, everyone, and welcome to the Iterum Therapeutics Third Quarter 2023 Financial Results and Business Update. My name is Harry, and I’ll be your operator today. [Operator Instructions] And I will now hand the call over to Louise Barrett, Senior Vice President, […]

Q3 2023 Iterum Therapeutics PLC Earnings Call

Iterum Therapeutics (NASDAQ:ITRM) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:00 AM. Here's what investors need ...

-- Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – --Resubmission of NDA for uUTI Expected in Q2 2024-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ende

Iterum Therapeutics (NASDAQ:ITRM) is set to give its latest quarterly earnings report on Tuesday, 2023-11-14. Here's what investors need ...

DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, November 14, 2023. Management will

– Topline Data Expected in Early Q1 2024 – – NDA Resubmission Expected in Q2 2024 – DUBLIN, Ireland and CHICAGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the completion of patient enrollment in its REASSURE (REnewed ASsessment of Sulopene

DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Society of America’s IDWeek 2023 conference taking place in Boston, MA from October 11-15, 2023. Dat

Q2 2023 Iterum Therapeutics PLC Earnings Call

Companies Reporting Before The Bell • Consolidated Water Co (NASDAQ:CWCO) is estimated to report quarterly earnings at $0.22 per ...

--Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 ----Cash Runway into Q3 2024-- DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2023.

DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Friday, August 11, 2023. Management will h

Avalo (AVTX) announces that it failed to meet the primary endpoint in its mid-stage poorly controlled non-eosinophilic asthma study. The stock falls 89% on Monday following the news.

Gainers G Medical Innovations (NASDAQ:GMVD) shares rose 45.2% to $2.41 during Friday's pre-market session. The market value of their ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the week with an overview of the biggest pre-market stock movers traders need to know about for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Gainers Iterum Therapeutics (NASDAQ:ITRM) shares moved upwards by 8.5% to $1.28 during Friday's after-market session. The company's ...

Gainers VYNE Therapeutics (NASDAQ:VYNE) shares rose 87.0% to $0.36 during Monday's after-market session. At the close, VYNE ...

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, ...

Gainers Scopus BioPharma (NASDAQ:SCPS) stock rose 112.9% to $0.5 during Thursday's pre-market session. The market value of their ...

Gainers Tenaya Therapeutics (NASDAQ:TNYA) shares increased by 16.4% to $2.84 during Thursday's after-market session. The company's ...

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares climbed 199.6% to close at $7.64 on Wednesday after the company announced ...

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are ...

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be ...

Gainers Canoo Inc. (NASDAQ: GOEV) shares jumped 79.9% to $4.2627 after Walmart signed a definitive agreement with the company to ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, traders! Investors seeking news of the biggest pre-market stock movers for Tuesday are in the right place. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.

Gainers Versus Systems Inc. (NASDAQ: VS) rose 66% to $0.7802 in pre-market trading. Versus Systems, last month, received NASDAQ ...

Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the ...

U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June. The Dow traded ...

Gainers Pliant Therapeutics (NASDAQ:PLRX) stock moved upwards by 104.5% to $18.16 during Monday's regular session. ...

Iterum Therapeutics plc(NASDAQ: ITRM) hasagreed with the FDAunder the special protocol assessment (SPA) process on ...

U.S. stocks traded lower midway through trading following the release of jobs report on Friday. The Dow traded down 0.50% to ...

Gainers Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's a new week and that means it's time to check in on all of the short squeeze stocks that traders need to keep an eye on! The post 5 Top Short Squeeze Stocks to Watch This Week appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Iterum Therapeutics (ITRM) stock is taking off on Monday as investors react to news of a clinical trial agreement with the FDA. The post Why Is Iterum Therapeutics (ITRM) Stock Up 73% Today? appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.

Gainers La Jolla Pharmaceutical (NASDAQ:LJPC) stock rose 80.8% to $6.13 during Monday's pre-market session. The ...

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company ...

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its ...

Iterum Therapeutics plc(NASDAQ: ITRM) has incurred aQ4 FY21 EPS loss of $(0.02)versus $(0.28) reported a year ago and ...

Iterum Therapeutics (NASDAQ:ITRM) reported its Q4 earnings results on Monday, March 28, 2022 at 07:00 AM. Here's what ...